FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 859 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Metastatic Breast Cancer: ESMO Clinical Practice Guideline May 29, 2026 Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma October 25, 2019 European Lung Cancer Congress 2024 March 7, 2024 Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens... February 23, 2023 Load more HOT NEWS How Therapy Helped Me Cope During Cancer: A Survivor’s Perspective “After a fire and a pandemic, it felt amazing to finish... Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in... Determination of the Incidence of Driver Mutations in Patients with NSCLC...
